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While newer antibiotics play a key role in treating methicillin-resistant Staphylococcus aureus (MRSA)
infections, knowledge of their real-world clinical impact is limited. We sought to quantify the effectiveness of
linezolid compared to that of vancomycin among MRSA-infected patients. This national retrospective cohort
study included adult patients admitted to all Veterans Affairs hospitals between January 2002 and June 2008,
infected with MRSA, and treated with either linezolid (oral or intravenous [i.v.]) or vancomycin (i.v.). Patients
were followed from their treatment initiation date until the event of interest, discharge, death, or December
2008. Utilizing propensity score methods, we estimated the treatment effects of linezolid primarily on time to
discharge and secondarily on time to all-cause in-hospital mortality, therapy discontinuation, and all-cause
90-day readmission with Cox proportional-hazard models. We identified 20,107 patients treated with linezolid
(3.2%) or vancomycin (96.8%). Baseline covariates were well balanced by treatment group within propensity
score quintiles and between propensity score matched patients (626 pairs). The discharge rate was significantly
higher among patients treated with linezolid, representing a decreased length of stay, in both the propensity
score adjusted (hazard ratio [HR], 1.38; 95% confidence interval [95% CI], 1.27 to 1.50) and matched (HR,
1.70; 95% CI, 1.44 to 2.00) analyses. A significantly decreased rate of therapy discontinuation, indicating longer
therapy duration, was observed in the linezolid group (adjusted HR, 0.64; 95% CI, 0.54 to 0.75; matched HR,
0.49; 95% CI, 0.36 to 0.65). In this clinical population of MRSA-infected patients, linezolid therapy was as
effective as vancomycin therapy with respect to in-hospital survival and readmission.
Limited treatment options exist for patients infected with
methicillin-resistant Staphylococcus aureus (MRSA). Vanco-
mycin has served as the gold standard of care for many years
(16, 28). However, the emergence of bacteria with decreased
vancomycin susceptibility has prompted the need for novel
antibiotics (16, 32). Linezolid, an oxazolidinone antibiotic, was
approved by the Food and Drug Administration in April 2000.
While a limited number of clinical trials have reported lin-
ezolid superiority, many have found efficacy equivalent to that
of vancomycin for the treatment of MRSA infections (10, 14,
30, 31, 33, 35–37). The few studies demonstrating significantly
higher clinical cure and survival rates with linezolid therapy
have been criticized for their limitations and conclusions, par-
ticularly the claim of linezolid superiority based on MRSA
subgroup analyses (3, 10, 11, 21, 22). Additionally, there are
conflicting data regarding length of stay decreases and length
of therapy when comparing linezolid and vancomycin therapies
(7, 15, 18–20, 30, 36).
Though randomized clinical trials provide key efficacy data
on newly approved agents, insight regarding their effectiveness
in clinical practice, particularly among diverse patient popula-
tions, and their effectiveness compared to that of standard
therapies is often lacking. Due to the increasing complexity of
treating MRSA infections, knowledge of the real-world clinical
impact of newer agents is needed for informed decision mak-
ing. We therefore sought to quantify the effectiveness of lin-
ezolid compared to that of vancomycin on clinical outcomes
among a national cohort of MRSA-infected patients admitted
to Veterans Affairs (VA) facilities.
(This work was presented in part at the 25th International
Conference on Pharmacoepidemiology and Therapeutic Risk
Management in Providence, RI, on 19 August 2009.)
MATERIALS AND METHODS
Data sources. We utilized standardized Veterans Health Administration na-
tional inpatient datasets, which contain International Classification of Diseases,
9th ed. (ICD-9), discharge diagnosis (up to 13 entries per admission) and pro-
cedure (up to 5 entries per day) codes (17). National extracts of inpatient and
outpatient records for prescriptions, laboratory tests, and select laboratory re-
sults were also included. This study was reviewed and approved by the Provi-
dence Veterans Affairs Medical Center and University of Rhode Island institu-
tional review boards.
Study design and population identification. We conducted a retrospective
cohort study among adult (18 years of age) patients admitted to VA hospitals
between 1 January 2002 and 30 June 2008 with a MRSA infection diagnosis code
(ICD-9 V09.0). If patients had more than one admission with a MRSA diagnosis
code, the first admission occurring during the study period was selected for
inclusion. We excluded patients with a concomitant diagnosis code for vanco-
mycin-resistant enterococcus (ICD-9 V09.8) or endocarditis (ICD-9 421.0, 421.1,
421.9, or 996.61), due to vancomycin nonutilization with the former and reported
linezolid treatment failure with the latter (26). From this eligible population, we
identified two groups of patients initiating therapy during the admission: those
receiving oral or intravenous (i.v.) linezolid (exposed group), as the oral formu-
* Corresponding author. Mailing address: Veterans Affairs Medical
Center (151), Research Building #35, 830 Chalkstone Avenue, Prov-
idence, RI 02908. Phone: (401) 273-7100, ext. 2339. Fax: (401) 457-
3305. E-mail: KerryTedesco@uri.edu.
 Published ahead of print on 26 July 2010.
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lation is 100% bioavailable, and those treated with i.v. vancomycin (comparison
group). Patients receiving greater than one dose of linezolid or vancomycin
therapy, but not both, during the admission were selected for inclusion. Figure 1
illustrates the inclusion and exclusion criteria applied for the identification of the
final study population.
Outcome definitions. The primary outcome of interest was time to discharge,
and the secondary endpoints evaluated were time to all-cause in-hospital mor-
tality, therapy discontinuation, and all-cause 90-day readmission. Therapy initi-
ation was used to define the index date of treatment. Time calculations were
made from the index date to the event date for each endpoint. Patients who died
during the admission were censored on their date of death, and those alive were
censored on their date of discharge. If the end of inpatient therapy occurred on
the date of discharge or death, patients were censored at these time points.
Patients who died during the index admission (n  1,537) were not included in
the follow-up for all-cause 90-day readmission to a medical unit in a VA hospital.
Patients without readmission records were censored on their date of death, 90
days from their discharge date, or on 31 December 2008.
Propensity score development. The Charlson comorbidity index and chronic
comorbidities were captured from ICD-9 codes in the year prior to admission
and during the index admission (23). Infection type was defined by the following
ICD-9 codes: bacteremia, 038.10, 038.11, 038.19, 038.8, 038.9, and 790.7; pneu-
monia, 482.40, 482.41, 482.49, 482.89, 482.9, 484.8, 485, 486, 510.0, 510.9, 513.0,
and 513.1; and skin and soft tissue, 680.0 to 680.9, 681.00 to 681.02, 681.10,
681.11, 681.9, 682.0 to 682.9, 684, 686.9, 704.8, 707.0 to 707.9, 998.31, 998.32,
998.51, 998.59, and 998.83 (8). To assess baseline differences between the two
study groups, we utilized Fisher’s exact or the 2 test for categorical data. For
continuous variables of interest, we used a t test for normally distributed data,
and the nonparametric Wilcoxon rank-sum test was used otherwise.
We employed propensity score methods, where the predicted probability of
treatment with linezolid was derived from unconditional logistic regression uti-
lizing a manual backward-elimination approach (1, 5, 25). Propensity scores
provide a means of balancing baseline covariates predictive of treatment, miti-
gating the unequal chance of receiving linezolid versus vancomycin, and are an
efficient method to control for confounding in pharmacoepidemiologic analyses
(1, 25). Our final model demonstrated fit (Hosmer and Lemeshow, P  0.477),
discrimination (C statistic, 0.784), and an absence of multicollinearity (5). Pro-
pensity score stratification into quintiles and 1:1 matching within a 0.01 propen-
sity score caliper range were implemented, related assumptions were assessed,
and subsequent covariate balance was reviewed.
Time-to-event analyses. We developed separate Cox proportional-hazard re-
gression models to quantify the effect of linezolid therapy compared to that of
vancomycin therapy for each of the aforementioned outcomes. In propensity
score adjustment, indicators of propensity score quintile (reference lowest quin-
tile) were included in the Cox models, while propensity score matching ac-
counted for matched linezolid- and vancomycin-treated pairs. We evaluated Cox
proportional-hazard model assumptions, including that of proportionality, with
formal tests and graphical displays (6). A hazard ratio (HR) greater than 1
indicated an increased probability of the event occurring sooner in the linezolid
group than in the reference vancomycin group. In terms of the study outcomes,
an HR greater than 1 would represent higher rates of discharge, mortality,
therapy discontinuation, and readmission among patients treated with linezolid.
In subgroup analyses, we assessed variations by infection type (24). We evaluated
various follow-up periods for all-cause readmission (30, 60, 180, and 365 days) in
sensitivity analyses. All analyses were performed using SAS software (version 9.1;
SAS Institute Inc., Cary, NC).
RESULTS
We identified 20,107 patients treated with linezolid (3.2%)
or vancomycin (96.8%). The majority of MRSA infections
occurred in Southern facilities. Several significant variations in
demographics and comorbidities, including gender, race, am-
putation, and para- or quadriplegia, were observed by treat-
TABLE 1. Demographics and comorbid conditions by
treatment group
Covariate
Resulta for patients treated
with:
P valueb
Linezolid
(n  637)
Vancomycin
(n  19,470)
Age in yr, mean (SDc) 65.1 (14.0) 64.2 (13.6) 0.089
Race 0.032
White 371 (58.2) 11,250 (57.8)
African-American 72 (11.3) 2,955 (15.2)
Other 7 (1.1) 186 (0.9)
Unknown/missing 187 (29.4) 5,079 (26.1)
Gender 0.010
Male 611 (95.9) 18,992 (97.5)
Female 26 (4.1) 478 (2.5)
Charlson comorbidity index,
median (IQRd)
2 (1–4) 2 (1–4) 0.135
Comorbid condition
Diabetes 251 (39.4) 7,966 (40.9) 0.445
Renal disease 191 (30.0) 5,214 (26.8) 0.073
Chronic respiratory disease 186 (29.2) 5,255 (27.0) 0.217
Coronary heart disease 185 (29.0) 5,464 (28.1) 0.589
Heart failure 127 (19.9) 3,774 (19.4) 0.728
Cancer 93 (14.6) 2,405 (12.4) 0.091
Amputation 48 (7.5) 1,013 (5.2) 0.010
Para- or quadriplegia 43 (6.8) 914 (4.7) 0.017
Hepatic disease 36 (5.7) 961 (4.9) 0.413
Cerebrovascular disease 32 (5.0) 1,322 (6.8) 0.080
HIV/AIDS 12 (1.9) 438 (2.3) 0.539
Transplant 9 (1.4) 193 (1.0) 0.294
Burns 4 (0.6) 83 (0.4) 0.358
a Data represent numbers of subjects, with percentages in parentheses, unless
otherwise indicated.
b Determined by t test, 2 test, Fisher’s exact test, or Wilcoxon rank-sum test
as appropriate.
c SD, standard deviation.
d IQR, interquartile range.
FIG. 1. Study inclusion and exclusion criteria applied for sample
identification. a, Patients aged 18 years and older, admitted to medical
units in Veterans Affairs hospitals between 1 January 2002 and 30 June
2008, with a MRSA diagnosis code. b, If a patient had multiple ad-
missions with a MRSA diagnosis during the study period, only the first
admission was included. c, Patients who received both vancomycin
(i.v.) and linezolid (i.v. or oral) during the admission. VRE, vancomy-
cin-resistant enterococcus.
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ment group (Table 1). Patients treated with linezolid were
exposed to a greater number of unique antibiotics in the 90
days before admission than those treated with vancomycin.
Linezolid use was more common in recent years, with concur-
rent decreases in vancomycin utilization over time. Previous
antibiotic exposure, facility region, surgery during the hospi-
talization, presence of a catheter while hospitalized, infection
type, time to treatment initiation, and treating specialty also
varied significantly between the linezolid and vancomycin
treatment groups (Table 2). No differences in baseline white
blood cell count, blood urea nitrogen, serum creatinine, or
creatinine clearance were observed by treatment group.
The propensity score was derived from an unconditional
logistic regression model controlling for age, gender, race,
region of facility, renal disease, amputation, para- or quad-
riplegia, cerebrovascular disease, previous linezolid and/or
vancomycin exposure, catheterization, surgery, infection
type, treating specialty, treatment year, time to treatment
initiation, age by renal disease, age by previous linezolid
and/or vancomycin exposure, age by infection type, age by
treatment year, age by time to treatment initiation, race by
region, race by treating specialty, race by time to treatment
initiation, region by amputation, region by previous lin-
ezolid and/or vancomycin exposure, region by treating spe-
cialty, amputation by time to treatment initiation, catheter
by infection type, catheter by treating specialty, infection
type by treatment year, infection type by time to treatment
initiation, and treatment year by time to treatment initia-
tion. Propensity score overlap between the linezolid and
vancomycin treatment groups was observed within quintiles.
Propensity score matching yielded 626 matched pairs, iden-
tifying a vancomycin-treated match for 98.3% of linezolid-
treated patients. Baseline covariates were well balanced by
treatment group within propensity score quintiles and be-
tween the matched linezolid- and vancomycin-treated pairs.
The results of propensity score adjusted and propensity
score matched analyses were comparable for each study out-
come (Fig. 2). Based on unadjusted Kaplan-Meier estimates of
event-free distribution functions, the median time to discharge
from treatment initiation was 6 days in the linezolid group and
9 days in the vancomycin group (likelihood ratio test, P 
0.001). The discharge rate was significantly higher among pa-
tients treated with linezolid in both the propensity score ad-
justed (HR, 1.38; 95% confidence interval [95% CI], 1.27 to
1.50) and matched (HR, 1.70; 95% CI, 1.44 to 2.00) analyses.
The median time to therapy discontinuation was 16 days in the
linezolid group and 13 days in the vancomycin group (P 
0.001). A significantly decreased rate of therapy discontinua-
tion was observed in the linezolid group (adjusted HR, 0.64;
95% CI, 0.54 to 0.75; matched HR, 0.49; 95% CI, 0.36 to 0.65).
In the overall population, 7.6% of patients died during the
hospitalization. The median survival times (P  0.381) and
90-day readmission event-free days (P  0.677) did not differ
significantly by treatment group. No associations between
treatment group and time to death or time to 90-day readmis-
sion were observed. These findings were consistent in sensitiv-
ity analyses of all-cause readmission, including 30-, 60-, 180-,
and 365-day follow-up periods. Of the total patients followed
after discharge, 9.2% had a MRSA infection diagnosis code
listed in a readmission occurring within the year after dis-
charge (9.2% for the linezolid group and 9.2% for the vanco-
mycin group).
In subgroup analyses by infection type (Fig. 3), no associa-
tions between treatment group and any of the study outcomes
were observed among patients with bacteremia. In the pneu-
monia subgroup, the discharge rate was significantly higher for
TABLE 2. Health care and antibiotic exposures and hospitalization-
related characteristics by treatment group
Covariate
Resulta for patients
treated with:
P valueb
Linezolid
(n  637)
Vancomycin
(n  19,470)
Previous hospitalizationc 380 (59.7) 10,935 (56.2) 0.081
Previous surgeryd 164 (25.8) 4,481 (23.0) 0.108
Previous antibioticse, mean
no. (SD)
1.9 (2.2) 1.4 (1.7) 0.001
Previous linezolid or
vancomycin
0.001
Linezolid 22 (3.5) 58 (0.3)
Vancomycin 163 (25.6) 6,039 (31.0)
Linezolid and vancomycin 80 (12.6) 225 (1.2)
Origin of admission 0.155
Home 518 (81.3) 16,149 (82.9)
Hospital 60 (9.4) 1,438 (7.4)
Nursing home 59 (9.3) 1,883 (9.7)
Region of facilityf 0.001
North 78 (12.2) 1,948 (10.0)
South 307 (48.2) 7,995 (41.1)
Midwest 105 (16.5) 4,351 (22.3)
West 147 (23.1) 5,176 (26.6)
Procedure during hospitalization
Surgery 146 (22.9) 5,705 (29.3) 0.001
Catheterization 93 (14.6) 6,062 (31.1) 0.001
Mechanical ventilation 47 (7.4) 1,593 (8.2) 0.467
Dialysis 27 (4.2) 1,010 (5.2) 0.287
MRSA infection type 0.001
Bacteremia 82 (12.9) 4,498 (23.1)
Pneumonia 126 (19.8) 2,718 (14.0)
Skin and soft tissue 232 (36.4) 6,965 (35.8)
Other/not specified 197 (30.9) 5,289 (27.1)
Treating specialty 0.002
Intensive care 82 (12.9) 2,985 (15.3)
Surgery 96 (15.1) 2,032 (10.4)
General medicine 362 (56.8) 11,384 (58.5)
Other 97 (15.2) 3,069 (15.8)
Treatment initiation 3 daysg 390 (61.2) 14,802 (76.0) 0.001
Yr of treatment 0.001
2002–2004 185 (29.0) 7,665 (39.4)
2005–2006 233 (36.6) 6,352 (32.6)
2007–2008 219 (34.4) 5,453 (28.0)
a Data represent numbers of subjects, with percentages in parentheses, unless
otherwise indicated.
b Determined by 2 test or Wilcoxon rank-sum test as appropriate.
c All-cause hospitalization to a Veterans Affairs medical unit in the previous
year.
d Any surgical procedure in the previous year.
e Previous exposures to unique antibiotics, at least one dose, in the 90 days
before admission.
f U.S. Census Bureau-defined regions.
g Treatment initiated within 3 days of the admission date.
4396 CAFFREY ET AL. ANTIMICROB. AGENTS CHEMOTHER.
linezolid-treated patients in propensity adjusted (HR, 1.60;
95% CI, 1.33 to 1.94) but not matched (HR, 1.85; 95% CI, 0.94
to 3.63) analyses. The therapy discontinuation rate among
those with skin and soft tissue infections was significantly
higher for linezolid-treated patients in propensity adjusted
(HR, 0.59; 95% CI, 0.42 to 0.82) but not matched (HR, 0.42;
95% CI, 0.15 to 1.18) analyses. In propensity score matched
analyses among patients with “other/not specified” infection
types, the 90-day readmission rate was significantly higher in
the linezolid group (HR, 4.60; 95% CI, 1.75 to 12.10).
DISCUSSION
We assessed the real-world effectiveness of linezolid com-
pared to that of vancomycin for the treatment of MRSA in-
fections among a large cohort of patients admitted to VA
hospitals. To our knowledge, this is the first national observa-
tional cohort study evaluating the impact of linezolid therapy
on time to discharge, in-hospital mortality, therapy discontin-
uation, and readmission. Time-to-event analyses revealed sig-
nificant differences between the linezolid and vancomycin
treatment groups in two of the outcomes evaluated.
Compared to vancomycin therapy, we found linezolid ther-
apy to be associated with a decreased length of stay after
treatment initiation, as indicated by the significantly higher
discharge rate. While length of stay was generally lower (1.0 to
3.5 days) for patients treated with linezolid compared to van-
comycin in randomized controlled trials, it was uncertain
whether these decreases would be experienced in clinical prac-
tice, particularly due to the small efficacy trial sample sizes and
MRSA subgroup analyses (7, 15, 18, 19, 30). In our pharmaco-
epidemiologic effectiveness study of patients hospitalized with
MRSA infections in VA facilities throughout the country, the
median length of stay was 3 days shorter among those treated
with linezolid compared to those treated with vancomycin. We
observed a decreased rate of therapy discontinuation in the
linezolid group, representing an increased length of therapy.
The reasons behind longer therapy duration in the linezolid
group compared to the vancomycin group are not clear but
may be related to prescribing practices as patients transition
out of the hospital.
Interpreting survival with linezolid treatment compared to
vancomycin in clinical trials has been complicated by conflict-
ing results, subgroup analyses, and small study populations (14,
31, 33, 35, 37). Two trials reported similar death rates by
treatment group in the overall study population but did not
describe the mortality rates in the MRSA subset (33, 35). A
MRSA subgroup analysis of two nosocomial pneumonia clin-
ical trials reported a higher survival rate among patients
treated with linezolid compared to those treated with vanco-
mycin (60/75 versus 54/85, P  0.030), which was not observed
in the overall study population (37). Alternatively, MRSA bac-
teremia survival did not vary by treatment group in a pooled
analysis of five randomized S. aureus bacteremia trials (odds
ratio [OR], 1.08; 95% CI, 0.41 to 2.85) (31). In our retrospec-
tive cohort study, treatment with linezolid therapy did not
significantly reduce the risk of death. Readmission rates were
similar by treatment group in clinical trials, although few stud-
ies reported such rates with very short follow-up times (35
days) (7, 19). In the overall MRSA cohort and subgroups of
pneumonia, skin and soft tissue infections, and bacteremia, we
did not find readmission rates to vary by treatment group.
This study has several limitations. There is always the po-
tential for residual confounding by unobserved covariates.
While the propensity score methodology successfully balanced
the baseline covariates assessed, it does not ensure subsequent
balance of unobserved covariates. In sensitivity analyses of
residual confounding, strong confounders, with a significant
confounder-outcome association and unequal distribution by
treatment group, could change the lower 95% confidence limit
of the hazard ratio to include one for the primary outcome.
The therapeutic impact of vancomycin could not be deter-
mined in this study, as peak and trough results were not avail-
FIG. 2. Hazard ratios of study outcomes for linezolid compared to vancomycin therapy. 1, Adjusted by propensity score quintiles (reference
quintile I). 2, Propensity score matched within a 0.01 caliper range.
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able for evaluation. The mean baseline creatinine clearance in
the vancomycin group was 59 ml/min, suggesting that a typical
dosing regimen of 1 g every 12 h would be sufficient to achieve
a therapeutic trough (12, 27). Additionally, we expect the av-
erage MIC of our national VA cohort to correspond with the
national average MIC of 1 mg/liter (9, 27, 34). Patients receiv-
ing both linezolid and vancomycin during the admission were
excluded, as patients failing treatment with vancomycin may
have been switched to linezolid.
We identified patients with MRSA infections from the V09.0
FIG. 3. Hazard ratios of study outcomes by infection type for linezolid compared to vancomycin therapy.
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ICD-9 code, as microbiological culture results could not be
obtained. Little information regarding the accuracy of this
diagnosis code exists. Despite this limitation, the code is used
in research to identify MRSA infections with a reportedly high
positive predictive value (92%) (2, 4, 29). Further, increased
sensitivity is expected when antibiotic treatment is taken into
account and when greater numbers of diagnosis entries are
available (4, 13, 29). While the possibility of MRSA infection
underascertainment exists, differential variation by treatment
group is doubtful. MRSA infections requiring inpatient treat-
ment may be captured with more consistency, which would
indicate better ascertainment among those treated with anti-
MRSA therapies.
In our study population, linezolid was utilized much less
frequently than vancomycin (3.2% versus 96.8%). In the lin-
ezolid group, few patients died during the hospitalization (37/
637) and subgroup analyses by infection type resulted in small
numbers, which affected our ability to discern differences by
treatment group. As more patients are treated with linezolid in
the future, a clearer picture of its effectiveness by infection type
and its impact on mortality will emerge. The generalizability of
this study is limited to VA patients.
In summary, linezolid was associated with a significantly
shorter length of stay and significantly longer duration of ther-
apy compared to vancomycin for the treatment of MRSA in-
fections. Among our national cohort of MRSA-infected pa-
tients, linezolid was as effective as vancomycin, with similar
in-hospital survival and readmission rates by treatment group.
Future research should include comprehensive pharmacoeco-
nomic analyses assessing costs related to length of stay and
duration of therapy comparing linezolid and vancomycin.
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